engleski

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS ON ERYTHROPOIESIS AND KIDNEY FUNCTION IN RENAL TRANSPLANT PATIENTS

Hypertension is present in about 60-80% of renal transplant patients (RTx). Angiotensin I receptor blockers (ARBs) are often given to those patients. It was reported that an intact renin-angiotensin system (RAS) may be an important factor of erythropoiesis. It is also known that ARBs may deteriorate kidney function.. The goal of this work was to examine influence of ARBs on erythropoiesis and kidney function in RTx. In this study, we analysed 47 RTx (19 men and 28 women, mean age 47, 1±9, 6 years) with stable transplant function. The time elapsed from transplantation to the introduction of ARBs was minimum 6 months (average 3, 7±2, 5 years). Excluding criteria were: serum creatinin value >140 µmol/L, taking ACE inhibitors and gastrointestinal bleeding. All patients received the triple immunosuppressive therapy (corticosteroid, mycophenolate mofetil, calcineurin inhibitor). Red blood cells count (RBCC), serum hemoglobin, hematocrit and serum creatinine values were measured before ARBs and 6 and 12 months after introducing therapy. At the end of follow up, there were no significant differences in RBCC, serum hemoglobin (p=0.08) and serum creatinine value (p=0.59). There were significant differences in hematocrit (p=0.03), after 6 and 12 months. In 14 patients whose hemoglobin values at the beginning were above 150 g/Lat baseline, a significant decrease was seen during follow up (p=0.003). We can conclude that there are no changes in serum creatinine values, i.e. kidney function in RTx treated with ARBs. There was no effect on RRCC and hemoglobin values. However, significant differences in RBCC and hemoglobin values were observed on

renal transplant patients; angiotensin receptor blockers; erythropoesis

nije evidentirano